Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

EHA 2023 | Exploring the evolving treatment landscape of myelofibrosis

Naveen Pemmaraju • 3 Jun 2023
EHA 2023
Myelofibrosis Myeloproliferative Neoplasms Fedratinib Momelotinib Pacritinib Ruxolitinib

Naveen Pemmaraju, MD, The University of Texas MD Anderson Cancer Center, Houston, TX, comments on the current and evolving treatment paradigm for myelofibrosis (MF), highlighting the need for novel agents to improve the life expectancy of these patients, and discussing approved and emerging JAK inhibitors, combination therapies with JAK inhibitors, and novel agents beyond JAK inhibitors.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.

More from Naveen Pemmaraju

1:40
TAG-AZA-VEN in the treatment of patients with newly diagnosed CD123+ AML
Naveen Pemmaraju • 11 Dec 2023
1:29
Exciting developments in the field of BPDCN
Naveen Pemmaraju • 11 Dec 2023
1:58
TRANSFORM-1: navitoclax + ruxolitinib vs placebo + ruxolitinib in patients with untreated MF
Naveen Pemmaraju • 11 Dec 2023
1:22
Interim analysis of a study evaluating pivekimab sunirine in patients with BPDCN
Naveen Pemmaraju • 3 Jun 2023

Related Videos

2:05
Donor lymphocyte infusion for relapsed myelofibrosis in the post-alloSCT setting
Alex Rampotas • 16 Apr 2024
2:52
JAK inhibitor combination therapy for the treatment of myelofibrosis
Ruben Mesa • 9 Dec 2023
1:30
XPORT-MF-034: selinexor + ruxolitinib combination therapy for MF
John Mascarenhas • 10 Dec 2023
1:38
Pelabresib plus ruxolitinib for the treatment of intermediate- and high-risk myelofibrosis
John Mascarenhas • 10 Dec 2023
The content of VJHemOnc is intended for healthcare professionals